Clinical Hepatology 2022
DOI: 10.1136/gutjnl-2022-iddf.92
|View full text |Cite
|
Sign up to set email alerts
|

IDDF2022-ABS-0058 Efficacy and response predictors of percutaneous radiofrequency ablation for treatment of intermediate stage hepatocellular carcinoma: a controlled clinical trial

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles